|Mode of transmission||By inhalation of respiratory tract droplets or by direct contact with respiratory tract secretions.|
|Incubation period||Unknown, but probably 2–4 days.|
|Period of communicability||May be prolonged. Non-communicable within 24–48 hours after starting effective antimicrobial therapy.|
|Disease burden||Children aged under 5 years, particularly those aged under 1 year.|
|Funded vaccines||DTaP-IPV-HepB/Hib (Infanrix-hexa). |
|Funded vaccine indications and schedule||At age 6 weeks, 3 months and 5 months: |
At age 15 months: Hib-PRP-T.
For (re-)vaccination of eligible patients.
|Vaccine efficacy/effectiveness||Hib disease has been almost eliminated in countries where Hib vaccine is used.|
|Public health measures||All contacts should have their immunisation status assessed and updated as appropriate. |
Rifampicin prophylaxis should be administered to contacts as appropriate.